The stock of Atossa Genetics Inc (NASDAQ:ATOS) is a huge mover today! The stock increased 10.82% or $0.21 during the last trading session, hitting $2.15. About 1.46M shares traded hands or 1027.54% up from the average. Atossa Genetics Inc (NASDAQ:ATOS) has declined 64.07% since April 26, 2016 and is downtrending. It has underperformed by 69.33% the S&P500.
The move comes after 5 months positive chart setup for the $8.06M company. It was reported on Nov, 29 by Barchart.com. We have $2.28 PT which if reached, will make NASDAQ:ATOS worth $483,600 more.
Analysts await Atossa Genetics Inc (NASDAQ:ATOS) to report earnings on March, 29. After $0.07 actual EPS reported by Atossa Genetics Inc for the previous quarter, Wall Street now forecasts -1,400.00% negative EPS growth.
According to Zacks Investment Research, “Atossa Genetics Inc. is a healthcare company focused on the development and marketing of cellular and molecular diagnostic risk assessment products for breast cancer. The Company’s diagnostic tests consist of medical devices which can collect fluid samples from the breast milk ducts. It is also conducting research on the treatment of pre-cancerous cells by using its FDA-cleared microcatheters to deliver, directly into the milk ducts, anti-cancer drugs that can be used to treat the pre-cancerous lesions. Atossa Genetics Inc. is headquartered in Seattle, WA.”
Insitutional Activity: The institutional sentiment decreased to 0 in Q2 2016. Its down 1.00, from 1 in 2016Q1. The ratio fall, as 4 funds sold all Atossa Genetics Inc shares owned while 2 reduced positions. 4 funds bought stakes while 2 increased positions. They now own 1.41 million shares or 3.81% more from 1.36 million shares in 2016Q1.
Blackrock Fund Advsrs accumulated 8,726 shares or 0% of the stock. Pnc Financial Svcs Group Inc holds 0% of its portfolio in Atossa Genetics Inc (NASDAQ:ATOS) for 4,350 shares. Vanguard Group holds 618,066 shares or 0% of its portfolio. Wells Fargo Mn holds 0% or 29,000 shares in its portfolio. Blackrock Institutional Trust Com Na holds 0% of its portfolio in Atossa Genetics Inc (NASDAQ:ATOS) for 111,034 shares. Kcg Holdg, a New Jersey-based fund reported 51,919 shares. Geode Capital Mgmt holds 0% of its portfolio in Atossa Genetics Inc (NASDAQ:ATOS) for 86,072 shares. Goldman Sachs Group reported 41,827 shares or 0% of all its holdings. Renaissance Technologies Llc holds 0% of its portfolio in Atossa Genetics Inc (NASDAQ:ATOS) for 352,262 shares. Royal State Bank Of Canada accumulated 991 shares or 0% of the stock. National Bank & Trust Of America De, a North Carolina-based fund reported 346 shares. Northern, a Illinois-based fund reported 22,677 shares. Moreover, Nomura Inc has 0% invested in Atossa Genetics Inc (NASDAQ:ATOS) for 44,073 shares. Commonwealth Equity Service accumulated 0% or 40,000 shares.
Another recent and important Atossa Genetics Inc (NASDAQ:ATOS) news was published by Quotes.Wsj.com which published an article titled: “News Atossa Genetics Inc.ATOS” on October 02, 2012.
ATOS Company Profile
Atossa Genetics Inc., incorporated on April 30, 2009, is a clinical-stage pharmaceutical firm focused on the development of therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The Company’s leading program uses its intraductal microcatheters, which deliver pharmaceuticals through the breast ducts. It has initiated a Phase II clinical study using its microcatheters to deliver fulvestrant as a treatment of ductal carcinoma in-situ (DCIS) and breast cancer. The Company’s second pharmaceutical program under development is Afimoxifene Topical Gel (AfTG) for the treatment and prevention of hyperplasia of the breast. It is also engaged in the process of evaluating other therapeutic candidates to treat other breast conditions, including breast cancer. The Company’s medical devices include the ForeCYTE Breast Aspirator and the FullCYTE Breast Aspirator. These devices are intended for the collection of nipple aspirate fluid (NAF) for cytological testing at a laboratory. It holds the worldwide exclusive rights to develop and commercialize AfTG for the treatment and prevention of hyperplasia of the breast. The active pharmaceutical ingredient in AfTG is Afimoxifene (4-hydroxytamoxifen), which is an active metabolite of tamoxifen. Afimoxifene is an anti-estrogen with an affinity for estrogen receptor that is up to approximately 50 fold higher compared with that of tamoxifen. AfTG is a transdermal gel formulation of Afimoxifene. It is evaluating AfTG for use in several patient populations, including high risk women as determined by family history; women with breast hyperplasia, and women with a biopsy showing either atypical hyperplasia or DCIS. AfTG can be dispensed from a metered-dose container. A total of over 16 Phase I and Phase II studies have been conducted in various indications in the United States, United Kingdom, France, Poland and Czech Republic.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.